Dr. Lorenzo Gianni - Oncologia Rimini

Bevacizumab + Letrozole
PR as best response on treatment, and there
were no complete responses, for a
response rate of 9% (95% CI, 3% to 22%).
Twenty-nine patients had SD for24 weeks.
Therefore, the clinical benefit rate (PRSD24
weeks) was 77% (95% CI, 61% to 88%).
Tiffany A. Traina et al. J Clin Oncol 2009;
28:628-633.
#595